Conclusions : This systematic review and meta- analysis showed that statin treatment significantly reduces systemic MDA concentrations .
Background : The effect of statins on oxidative stress markers , such as malondialdehyde ( MDA ) , is still a matter of debate .
We sought to address this issue by conducting a systematic review and meta- analysis of published data on the effect of statin treatment on systemic MDA concentrations .
Atorvastatin treatment increases plasma bilirubin but not HMOX1 expression in stable angina patients
Abstract Background . In vitro and animal studies indicate that statins increase heme oxygenase-1 gene ( HMOX1 ) expression , which then , presumably , increases plasma bilirubin concentration . However , clinical confirmation that statins concomitantly increase HMOX1 expression and plasma bilirubin concentration is lacking . We hypothesized that in patients with stable angina  atorvastatin therapy ( 20 mg/day for 10 weeks ) concomitantly increases total bilirubin concentration and HMOX1 expression , as assessed non-invasively by plasma analysis . Methods . In 44 patients with stable angina plasma concentrations of total bilirubin , HMOX1 mRNA and HMOX1 protein were measured before and after the statin treatment , as well as plasma concentrations of oxidized low-density lipoprotein ( OxLDL ) , malondialdehyde ( MDA ) , monocyte chemoattractant protein ( MCP-1 ) and C-reactive protein ( CRP ) . Results . Atorvastatin treatment increased total bilirubin concentration ( median 6.95 μmol/L vs. 8.55 , + 23.02 % ; p < 0.001 ) , but did not change plasma HMOX1 mRNA and HMOX1 protein concentrations . Plasma concentrations of OxLDL ( − 31.85 % , p < 0.001 ) , MCP-1 ( − 16.20 % , p = 0.020 ) and CRP ( − 7.32 % , p = 0.010 ) were decreased but MDA was not decreased ( 15.32 % , p = 0.107 ) . Within subjects , increment of plasma bilirubin concentration did not correlate with the changes in HMOX1 mRNA and protein concentrations , but correlated with low-density lipoprotein cholesterol decrement ( r = − 0.374 , p = 0.012 ) . Bilirubin increment did not correlate with the changes in oxidative and inflammatory markers . Conclusion . Our prospect i ve observational trial finally confirms that atorvastatin ( 20 mg/day for 10 weeks ) increases plasma total bilirubin concentration . However , it seems that this effect is HMOX1-independent
Conclusions : This systematic review and meta- analysis showed that statin treatment significantly reduces systemic MDA concentrations .
Background : The effect of statins on oxidative stress markers , such as malondialdehyde ( MDA ) , is still a matter of debate .
We sought to address this issue by conducting a systematic review and meta- analysis of published data on the effect of statin treatment on systemic MDA concentrations .